5 completed, 5 unknown. 7 Phase 2, 2 Phase 1, 1 Not applicable.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 7 | Completed 4, Unknown 3 |
| Phase 1 | 2 | Completed 1, Unknown 1 |
| Not applicable | 1 | Unknown 1 |
Follow Yongchang Zhang: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Trial of Tumor Vaccine Used for Adjuvant Therapy in Post Radical Operation Patients With Lung Cancer Tumor Vaccine - Lung Cancer | Phase 1 / Phase 2 | Unknown | Yongchang Zhang | 30 | 2024-01-16 | 2023-12-29 |
| A Retrospective Study: Evaluation of the Efficacy of Immunotherapy With Rare Mutations in Non-small Cell Lung Cancer immunity therapy - Non Small Cell Lung Cancer | Unknown | Yongchang Zhang | 186 | 2023-01-01 | 2024-09-19 | |
| Radiotherapy + Sintilimab + Bevacizumab Biosimilar for uHCC With PVTT radiotherapy combined with sintilimab and bevacizumab biosimilar - Hepatocellular Carcinoma Non-resectable | Not applicable | Unknown | Yongchang Zhang | 35 | 2022-08-01 | 2022-09-07 |
| Toripalimab Combined With Double Platinum-based Chemotherapy for Initially Unresectable NSCLC Toripalimab - Advanced Non Small Cell Lung Cancer | Phase 2 | Completed | Yongchang Zhang | 40 | 2020-01-16 | 2024-08-09 |
| First-in-Human Phase I/II Study of FHND-9041 in Patients With EGFR Mutated Advanced Non-Small Cell Lung Cancer FHND-9041 - Non-small Cell Lung Cancer, EGFR Gene Mutation | Phase 1 / Phase 2 | Completed | Yongchang Zhang | 124 | 2019-06-27 | 2024-07-25 |
| PD-1 Combined With Pyrotinib for Chemotherapy Failure HER2 Insertion Mutation Advanced NSCLC PD-1 Combined With Pyrotinib - HER2 Insertion Mutation Positive Advanced NSCLC | Phase 2 | Unknown | Yongchang Zhang | 30 | 2019-01-30 | 2024-09-19 |
| Sintilimab Combined With Docetaxel for Standard Chemotherapy Failure Non-driver Gene Mutation Metastatic Non-small Cell Lung Cancer Sintilimab Combined With Docetaxel Monotherapy - Non-small Cell Lung Cancer | Phase 2 | Completed | Yongchang Zhang | 30 | 2019-01-01 | 2022-03-02 |
| Study of Anlotinib Combined With Docetaxel in Non-Driver Mutation Non-squamous NSCLC: the Save Study Anlotinib and Docetaxel - Non-Squamous Non Small Cell Lung Cancer | Phase 2 | Unknown | Yongchang Zhang | 43 | 2018-08-01 | 2023-12-27 |
| Procalcitonin to Predict Infection After Gastrectomy for Gastric Cancer Gastric Cancer | Completed | Yongchang Zhang | 552 | 2018-06-01 | 2019-09-24 | |
| Apatinib Combined With Vinorelbine for Non-driver Gene Mutation Non-small Cell Lung Cancer Apatinib Combined With Vinorelbine - Advanced Non Small Cell Lung Cancer | Phase 2 | Completed | Yongchang Zhang | 30 | 2017-01-01 | 2020-02-17 |
Carcinoma, Non-Small-Cell Lung (3) · Infections (1) · Lung Neoplasms (1) · Stomach Neoplasms (1)
Cancer Vaccines (1) · Docetaxel (1) · Immunization, Passive (1) · Platinum Compounds (1) · Vinorelbine (1) · anlotinib (1) · pyrotinib (1) · sintilimab (1) · toripalimab (1)
China (10)
Yongchang Z MD, MD (2) · Hua Xiao (1) · Jia Luo, Professor (1) · Nong Yang, MD (1) · Wenxiang Wang, MD, PhD (1)
PMID 26135691, PMID 27010585, PMID 27049766, PMID 29572591, PMID 32191330, PMID 39892382